EA
CYTK icon

Emerald Acquisition’s Cytokinetics CYTK Stock Holding History

Emerald Acquisition’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-128,133
Closed -$1.22M – 2995
2016
Q2 		$1.22M Buy
+128,133
New +$1.05M ﹤0.01% 2069

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Emerald Acquisition's CYTK Position: Q3 2016 in Review

Emerald Acquisition sold out of Cytokinetics (CYTK) in Q3 2016, closing a stake of 128,133 shares — an estimated $1.22M sold.

Emerald Acquisition first reported a position in CYTK in Q2 2016 and held it in 1 quarter. The position peaked at $1.22M in Q2 2016. 91 funds tracked by Wall St. Rank hold CYTK as of Q3 2016.

  • Emerald Acquisition reported no remaining Cytokinetics position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 128,133 Cytokinetics shares in Q3 2016, an estimated $1.22M.
  • Emerald Acquisition first reported a position in Cytokinetics in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Cytokinetics position peaked at $1.22M in Q2 2016.
  • 91 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.